Lenalidomide [191732-72-6]
Cat# T1642-1mL
Size : 1mL
Brand : TargetMol
Lenalidomide
Contact us for more batch information
Purity:99.97%
Resource Download
COA HPLC HNMR
Lenalidomide
Catalog No. T1642Cas No. 191732-72-6
Lenalidomide (CC-5013) is an immunomodulator with oral activity. Lenalidomide is a ligand for the ubiquitin E3 ligase cereblon (CRBN), which selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, via the CRBN-CRL4 ubiquitin ligase, and is commonly used in the synthesis of PROTAC products.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. Pack Size | |
---|---|
50 mg | |
100 mg | |
200 mg | |
500 mg | |
1 g | |
1 mL x 10 mM (in DMSO) |
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
Description | Lenalidomide (CC-5013) is an immunomodulator with oral activity. Lenalidomide is a ligand for the ubiquitin E3 ligase cereblon (CRBN), which selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, via the CRBN-CRL4 ubiquitin ligase, and is commonly used in the synthesis of PROTAC products. |
Targets&IC50 | TNF-α:13 nM |
In vitro | METHODS: Six malignant glioma cell lines, A-172, AM-38, T98G, U-138MG, U-251MG, and YH-13, were treated with Lenalidomide (0.01-100 µM) for 72 h, and cell counts were detected by Coulter counter assay. RESULTS: Lenalidomide inhibited cell counts of all malignant glioma cells in a concentration-dependent manner. [1] METHODS: DCs were differentiated from BM CD14+ cells from MM patients, treated with Lenalidomide (0.1-1 µM) for 8 days and analyzed for DC maturation markers by flow-cytometry. RESULTS: Despite a reduction in the number and percentage of mature DCs, Lenalidomide significantly increased the expression of HLA-DR, CD86, and CD209 in DCs derived from BM over the range of concentrations achieved in MM patients. [2] |
In vivo | METHODS: To test the antitumor activity in vivo, Lenalidomide (25 mg/kg) was injected intraperitoneally into C57BL/KaLwRij or B6-SCID mice bearing 5TGM1 tumors once daily for 21 days. RESULTS: Lenalidomide inhibited tumor growth and prolonged survival of C57BL/KaLwRij mice bearing 5TGM1 tumors.Lenalidomide significantly increased the number of IFN-γ-secreting CD4+ and CD8+ T cells but had no effect on NK cells and B cells in the B6-SCID mouse model. Lenalidomide slightly decreased the number of CD25+Foxp3+ T cells in vivo, but increased perforin expression in CD8+ T cells.Lenalidomide promoted type 1 antitumor immune responses in vivo. [3] |
Cell Research | The human NSCLC cell lines Lu-99, H1299, A549, EBC1, and H460 were cultured in RPMI-1640 medium containing 10% fetal bovine serum and antibiotics at 37°C in a humidified chamber containing 5% CO2. Cells were seeded into 60-mm culture dishes (2x10^5 cells per dish) with various concentrations of lenalidomide and incubated for various times [1]. |
Animal Research | Mice were administered sterile preparations of lenalidomide normalized to body weight. Intravenously (IV) dosed animals received drug by bolus tail vein injections, and extravascularly dosed mice received drug by bolus intraperitoneal injections (IP) or oral gavage (PO). Dosing solution, concentrations were adjusted so dose volumes ranged between approximately 100 and 150 μL for IV injections and between approximately 150 and 250 μL for IP and PO dosing in the pharmacokinetic study. However, for the range-finding study, increased dose volumes were used (up to 200 μL IV, 300 μL IP, and 600 μL PO, per approved animal use protocol) to explore elevated lenalidomide doses. The bolus injection rates for all IV, IP, or PO injections were less than 5 s. Concentrations of dosing solutions were verified by liquid chromatography-mass spectrometry [4]. |
Alias | CC-5013 |
Molecular Weight | 259.26 |
Formula | C13H13N3O3 |
Cas No. | 191732-72-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 50 mg/mL (192.86 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSO
main solution, add 300 μLPEG300
mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O
mix well and clarify
Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
myelomaInhibitorCRL4ligaseIKZF1Ligands for E3 LigaseE3 ligase-recruiting MoietyApoptosisimmunomodulatorycereblonanalogmultipleCC5013inhibitligandLenalidomideCC 5013IKZF3Molecular Gluesdegradation
Related Tags: buy Lenalidomide | purchase Lenalidomide | Lenalidomide cost | order Lenalidomide | Lenalidomide chemical structure | Lenalidomide in vivo | Lenalidomide in vitro | Lenalidomide formula | Lenalidomide molecular weight